Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

67.29 +1.72 (+2.62%)

Streaming Delayed Price Updated: 2:18 PM EDT, Sep 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,302,082
Open	65.07
Bid (Size)	67.23 (800)
Ask (Size)	67.35 (100)
Prev. Close	65.57
Today's Range	64.36 - 67.33
52wk Range	50.50 - 93.42
Shares Outstanding	160,500,999
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status ↗

September 26, 2026

BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a...

Via MarketBeat

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

September 23, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Performance

YTD	-14.0%	-14.0%
1 Month	-12.2%	-12.2%
3 Month	-6.6%	-6.6%
6 Month	-3.0%	-3.0%
1 Year	+29.5%	+29.5%

More News

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 18, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

September 09, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup ↗

August 11, 2026

Via Chartmill

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

September 02, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Participate in September Investor Conferences

September 01, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

August 31, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

August 30, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

August 26, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

August 24, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio (BBIO) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Via The Motley Fool

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Via The Motley Fool

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. ↗

August 14, 2026

Via The Motley Fool

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

August 14, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

August 13, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 11, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Q2 Earnings Call Highlights ↗

August 10, 2026

Via MarketBeat

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

August 10, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET

August 03, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree. ↗

August 02, 2026

Via The Motley Fool

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

July 22, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

July 13, 2026

Via MarketBeat

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 10, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

There are notable gap-ups and gap-downs in today's session. ↗

July 09, 2026

Via Chartmill

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?

Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?

BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?

The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market

What is the current price of BridgeBio Pharma, Inc. - Common Stock?

The current price of BridgeBio Pharma, Inc. - Common Stock is 67.29

When was BridgeBio Pharma, Inc. - Common Stock last traded?

The last trade of BridgeBio Pharma, Inc. - Common Stock was at 09/28/26 02:18 PM ET

What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?

The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 10.80B

How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?

BridgeBio Pharma, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.